# Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

> **NCT02873260** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 48 (estimated)

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** TetraVax-DV-TV005
- **BIOLOGICAL:** rDEN3Δ30
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02873260
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2018-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873260, "Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02873260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*